SECOND AMENDMENT TO RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT
EXHIBIT 10.33
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. |
SECOND AMENDMENT
TO
RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT
This Second Amendment to Research Services, License and Collaboration Agreement (this “Second Amendment”) is entered into as of January 31, 2023 (the “Second Amendment Effective Date”) by and between Repare Therapeutics, Inc., a corporation organized and existing under the laws of Canada and having its principal place of business at ▇▇▇▇ ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇, ▇▇-▇▇▇▇▇▇▇, ▇▇▇▇▇▇, ▇▇▇ ▇▇▇, ▇▇▇▇▇▇ (“Repare”) and Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan and having an address of ▇-▇, ▇▇▇▇▇▇▇▇▇▇▇▇ ▇-▇▇▇▇▇, ▇▇▇▇-▇▇, ▇▇▇▇▇ ▇▇▇-▇▇▇▇, ▇▇▇▇▇ (“Ono”). Repare and ▇▇▇ may each be referred to herein as a “Party” or collectively as the “Parties.”
WHEREAS, ▇▇▇▇▇▇ and ▇▇▇ entered into that certain Research Services, License and Collaboration Agreement, dated as of January 31, 2019, as amended by First Amendment, dated as of October 29, 2021 (the “Agreement”); and
WHEREAS, the Parties wish to amend the Agreement to extend the Research Term and revise the Licensed Drug Candidate selection process;
NOW, THEREFORE, the Parties, intending to be legally bound, hereby agree as follows:
1.142 “Research Term” means the period commencing on the Effective Date and ending upon the earlier of (a) July 31, 2023, or (b) the date of submission of the first IND in the United States or in Japan. Any extension of the Research Term will require the mutual written agreement of both Parties.
3.3 DC Selection Meeting. The Parties shall hold a meeting at the date and time agreed upon by the Parties, but no later than the earlier of (a) the date of submission of the first IND in the United States or in Japan or (b) [***], in order to discuss the selection of one potential Licensed Drug Candidate among the Drug Candidates to move toward further Development and Commercialization by the Parties (the “DC Selection Meeting”).
[THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK]
IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Second Amendment to Research Services, License and Collaboration Agreement to be executed by their respective duly authorized officers as of the Second Amendment Effective Date.
REPARE THERAPEUTICS, INC.
|
|
By: |
/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇ |
Name: |
▇▇▇▇▇ ▇. ▇▇▇▇▇ |
Title: |
President & CEO |
ONO PHARMACEUTICAL CO., LTD
|
|
By: |
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇ |
Name: |
▇▇▇▇▇ ▇▇▇▇▇▇▇ |
Title: |
Senior Director, Research Center of Oncology |